Purnell Jennifer, Shaffrey Isabelle, Ellis Scott, Deland Jonathan, Henry Jensen, Demetracopoulos Constantine
Foot & Ankle Department, Hospital for Special Surgery, New York, NY, USA.
Foot Ankle Int. 2024 Feb;45(2):124-129. doi: 10.1177/10711007231209938. Epub 2023 Nov 23.
As the number of total ankle arthroplasties (TAAs) performed annually increases, there is increased demand for modular revision implants. There is limited early survivorship and clinical outcome data for the INVISION Total Ankle Arthroplasty System (Wright Medical Technology/Stryker). This study aims to determine early implant survivorship, complications, and radiographic and patient-reported outcomes (PROs) of the INVISION implant in the revision setting.
This is a single-institution retrospective review of adult patients who underwent revision TAA with the INVISION implant with minimum 2-year follow-up. Demographics, complications, radiographic data, and PROs (PROMIS) were collected. The primary outcome was implant survivorship. Secondary outcomes were reoperation, radiographic complications, and PROs.
Nineteen patients underwent revision INVISION TAA with mean follow-up of 3.5 years. INVISION revision TAA was used for tibial (n = 6) or talar (n = 7) component subsidence, recurrent tibiotalar malalignment (valgus = 1, varus = 3), and postinfection bone loss (n = 2). Two-year implant survivorship was 100%. There were no reoperations. One patient had lucency of the talar component at 6 months post TAA revision with INVISION. One patient had talar subsidence at final follow-up. Two-year postoperative follow-up PROMIS domains improved significantly ( < .05).
There was excellent short-term survivorship of the INVISION TAA implant, with no failures. There were significant improvements in PROs and low rates of subsidence and lucencies. The results of this study support using the INVISION implant in the revision TAA setting.
Level III, retrospective cohort.
随着每年全踝关节置换术（TAA）数量的增加，对模块化翻修植入物的需求也在增加。关于INVISION全踝关节置换系统（Wright Medical Technology/Stryker）的早期生存率和临床结果数据有限。本研究旨在确定INVISION植入物在翻修情况下的早期植入物生存率、并发症以及影像学和患者报告结局（PROs）。
这是一项单机构回顾性研究，纳入接受INVISION植入物翻修TAA且随访至少2年的成年患者。收集人口统计学资料、并发症、影像学数据和PROs（PROMIS）。主要结局是植入物生存率。次要结局是再次手术、影像学并发症和PROs。
19例患者接受了INVISION TAA翻修，平均随访3.5年。INVISION翻修TAA用于胫骨（n = 6）或距骨（n = 7）部件下沉、复发性胫距关节排列不齐（外翻 = 1，内翻 = 3）以及感染后骨丢失（n = 2）。两年植入物生存率为100%。无再次手术。1例患者在使用INVISION进行TAA翻修后6个月出现距骨部件透亮。1例患者在最终随访时出现距骨下沉。术后两年随访的PROMIS领域有显著改善（P <.05）。
INVISION TAA植入物短期生存率极佳，无失败病例。PROs有显著改善，下沉和透亮发生率低。本研究结果支持在TAA翻修情况下使用INVISION植入物。
III级，回顾性队列研究。
